Background/Objectives: This study aimed to investigate whether higher homocysteine and lower vitamin B12 concentrations increase the risk of future nursing home (NH) admission and all-cause mortality in independently living older persons. Subjects/Methods: In total, 1117 independently living participants (mean age ¼ 75.1, s.d. ¼ 6.4) were included in this prospective sub-study of the Longitudinal Aging Study Amsterdam. EDTA plasma samples, collected in 1995-1996, were analysed for total homocysteine (mmol/l). Time to NH admission was assessed using a follow-up until [2002][2003]. In addition, we studied mortality until 1 June 2007. Cox proportional hazards models were used to examine the association between homocysteine in quartiles and risk of NH admission and mortality. Results: During follow-up, 126 persons (11.3%) were admitted to NHs, and 513 persons (45.9%) deceased. In men, no significant associations were observed. In women, after adjustment for confounding, the highest quartile of homocysteine was associated with a significantly higher risk of NH admission compared with the first quartile (hazard ratio (HR) ¼ 2.97, 95% confidence interval (CI) ¼ 1.36-6.49). Both women in the third and the fourth quartile of homocysteine had a significantly higher mortality risk (HR ¼ 1.70, 95% CI ¼ 1.08-2.65 and HR ¼ 1.91, 95% CI ¼ 1.22-3.00, respectively) compared with the first quartile. Vitamin B12 was not related to an increased risk of NH admission and mortality. Conclusions: Elevated plasma homocysteine is associated with an increased risk of NH admission and mortality in older women, but not in older men.
Introduction
In the older population, elevated plasma homocysteine concentrations are present in 30-50% of the persons (de Bree et al., 2005) . Plasma homocysteine concentrations are influenced by a complex interaction of environmental and genetic factors, such as nutrition, lifestyle, renal function and hormonal factors. Elevated levels can be reduced by vitamin B6, B12 or folic acid supplementation, which are essential co-factors in the homocysteine metabolism (van Oort et al., 2003; Eussen et al., 2005) .
Hyperhomocysteinemia is associated with several chronic diseases, such as cerebro-and cardiovascular disease (CVD) (for example, Antoniades et al., 2009) , cognitive impairment (for example, Seshadri et al., 2002; Durga et al., 2007; Haan et al., 2007) . A growing body of evidence indicates that hyperhomocysteinemia is associated with impaired physical functioning (Kado et al., 2002; Soumare et al., 2006; Kuo et al., 2007; Rolita et al., 2010) and osteoporosis and fracture risk (for example, van Meurs et al., 2004; McLean et al., 2008) . The combination of both high homocysteine and low vitamin B12 concentrations further increased the fracture risk (Dhonukshe-Rutten et al., 2005) . Moreover, low vitamin B12 has been linked to cognitive deficits . Hence, homocysteine and vitamin B12 are risk factors for a unique combination of chronic conditions in older persons that predispose to physical dependency.
The hypothesis that homocysteine and vitamin B12 predict dependency is supported by the observation that homocysteine is associated with mobility decline, disability and functional impairment (Kado et al., 2002; Marengoni et al., 2004; Kuo et al., 2007; Rolita et al., 2010) . Additionally, it is suggested that vitamin B12 is a marker of the frailty syndrome Matteini et al., 2008) .
Further support might be found in the association of homocysteine and vitamin B12 with nursing home (NH) admission. To our knowledge, the relation between homocysteine or vitamin B12 and the risk of NH admission has never been investigated. Previous research investigated homocysteine related to the risk of mortality, providing empirical support for an increased mortality rate with elevated concentrations of homocysteine in normal older subjects, patients with CVD, renal failure and mental illness (for example, Nygard et al., 1997; Bostom et al., 1999; Kark et al., 1999; Shishehbor et al., 2008; Nilsson et al., 2009) .
The current prospective study aimed to examine whether higher homocysteine concentrations and lower vitamin B12 concentrations are associated with an increased risk of NH admission and all-cause mortality in independently living older persons. Compared with previous studies investigating mortality risk, this study was performed in a large stratified sample of the older Dutch population with a long follow-up duration. As homocysteine is associated with cognitive impairment, CVD and functional impairments, these independence-reducing conditions might have a mediating role in the potential associations. We hypothesised that elevated plasma homocysteine and reduced serum vitamin B12 are associated with an increased risk of NH admission and mortality, and that these associations are mediated by CVD, cognitive impairment and functional impairment.
Materials and methods

Study sample
In the Longitudinal Aging Study Amsterdam (LASA), an ongoing cohort study in the older population in the Netherlands, data on physical, cognitive, emotional and social functioning were collected. The sample was drawn from population registers of 11 municipalities in three areas in the west (Amsterdam and vicinity), north-east (Zwolle and vicinity) and the south-east (Oss and vicinity) of the Netherlands, stratified by age and gender according to expected 5-year mortality and urbanisation grade. Every 3 years a new measurement cycle was conducted, with the first cycle starting in 1992-1993. In total, 3107 respondents participated in the first cycle. Procedures of the data collection and sampling have been described elsewhere in detail (Smith and de Vries, 1994) .
As a result of the availability of blood samples, 1995-1996 was considered as baseline year in the current sub-study of LASA. In the medical interview of 1995-1996, 1509 respondents aged 65 years and older participated. Blood samples were obtained in 1352 respondents. In 1301 of these respondents, homocysteine concentrations could be determined. Respondents who had missing information on homocysteine (n ¼ 208) or vitamin B12 (additional n ¼ 44) or who had serum vitamin B12 level 4800 pmol/l (n ¼ 32) were excluded. Respondents who were not living independently at baseline, that is, who were living in an institution, or who had missing information on potential confounders or follow-up (n ¼ 108) also were excluded. Hence, 392 respondents were excluded. The remaining sample contained 1117 respondents (see also Figure 1 ).
All respondents signed informed consent. The study was approved by the Medical Ethics Committee of VU University Medical Center.
NH admission
A NH is defined as a chronic care facility, mainly for older persons. NH admission was assessed between baseline and the measurement cycle of 2002-2003, a 6-year follow-up duration. It was assessed during the main interviews, by contacting a proxy, using information on death certificate in case the respondent deceased or by using information assessed during the last study contact in case of drop-out. For every respondent, the person-time they were at risk to be admitted to a NH, that is, the time they did not live in a NH, was determined since baseline .
Mortality
Death was confirmed by death certificates from the registries of the municipalities in which the respondents were living. All deaths were recorded between baseline and 1 June 2007, an 11-year follow-up duration. Survival time was calculated as the time between the date of the baseline interview and the date of death. If respondents were not deceased, person-time was calculated as the time between the date of the baseline interview and 1 June 2007.
Homocysteine and vitamin B12
Blood samples were obtained in the morning after a light breakfast consisting of tea and toast. Samples were centrifuged Baseline measurement LASA (1992 -1993 n=3107
Second cycle LASA (1995) (1996) n=2545
Medical interview (1995) (1996) Blood availability n=1352
Valid homocysteine n=1301
Study sample n=1117
Excluded: Missing vitamin B12 (n=44) Vitamin B12 >800 pmol/L (n=32) Not independently living (n=16)
Missing data (n=84) Missing follow-up (n=8)
Respondents aged 65 years n=1509 Figure 1 Flow chart of the study sample.
and stored at À20 1C until analysis. Total plasma homocysteine concentrations (mmol/l) were measured in EDTA plasma, using the Abbott IMx analyser (Abbott Diagnostics, Abott Park, IL, USA). This method uses fluorescence polarisation immunoassay to obtain total plasma homocysteine concentrations. The inter-assay coefficient of variation was 4%. Serum vitamin B12 (pmol/l) was determined with a competitive luminescence immunoassay on an automated ACS 180 System (Bayer Diagnostics, Mijdrecht, The Netherlands). The inter-assay coefficient of variation was 5%.
Potential effect modifiers, confounders and mediators Potential effect modifiers, confounders and mediators were studied at baseline. Gender was regarded as an effect modifier, as sex differences in the distribution of homocysteine are known. Age, level of education, region of living, serum creatinine, body mass index, alcohol use, smoking and physical activity level were considered to be confounders. Cognitive impairment, the presence of CVD and functional impairment were regarded as potential mediators. Level of education was assessed by asking respondents' highest level of education completed, ranging from 1 to 9, with score 1 representing not completed elementary school, and 9 representing university education. Region was outlined as living in or in the surroundings of Amsterdam, Zwolle or Oss, cities in the west, northeast and south of the Netherlands, respectively. Serum creatinine (mmol/l) was analysed using Jaffe alkaline picrate reaction with a Hitachi 747 analyser (Roche Diagnostics, Woerden, The Netherlands). Body mass index (kg/m 2 ) was calculated as body weight divided by body length squared. Alcohol consumption was assessed by asking for the number of alcoholic units consumed on a drinking day over the past year, and the number of days of the week in which alcohol was consumed (Garretsen, 1983 ). Alcohol consumption was categorised as no, light, moderate or excessive drinking. Moderate drinking was defined as X6 drinks for 1-3 days per month, 4-5 drinks for 1-4 days per week or 2-3 drinks for 3-7 days a week. Light drinking was defined as drinking less than moderate, and excessive as drinking more than moderate. Smoking was defined as no, former or current smoking. Physical activity (min/day) was assessed with the LASA physical activity questionnaire, a validated and reliable measure to determine physical activity in an older population (Stel et al., 2004) . Cognitive impairment was measured with the use of the Mini Mental State Examination, a widely used questionnaire to monitor global cognitive functioning. The questionnaire addresses six different cognitive domains: orientation, registration, attention, recall, language and visual construction. The total score ranges from 0 to 30. Cognitive impairment was defined as having a score o24 (Tombaugh and McIntyre, 1992) . The presence of CVD was ascertained using data derived from respondents self-report, medication use during the past 2 weeks and data from the general practitioner. CVD was defined as the presence of at least one of the following diagnoses: angina pectoris, myocardial infarction, congestive heart failure, peripheral arterial disease, cardiac arrhythmia or cerebro-vascular accident (including transient ischaemic attack) (Schalk et al., 2006) . Functional impairment was assessed with the use of a 6-item questionnaire about difficulties in daily living. The score ranged from 0 to 6, with functional impairment being defined as having a score of 2 or more.
Statistical analyses
Analyses were performed with SPSS, version 15.0 for Windows (SPSS Inc., Chicago, IL, USA). Homocysteine and vitamin B12 were analysed in gender-specific quartiles, with the first quartile of homocysteine and the fourth quartile of vitamin B12 being the reference groups. The associations with NH admission and mortality were examined using Cox proportional hazards models. 'Survival time' was defined as the time to admission or time to death, respectively. In the first model, the univariable association was examined. In the second model, adjustments were made for the personal characteristic. Lifestyle variables were added to the third model. In the fourth model, vitamin B12 was added in the homocysteine analyses, and vice versa. The assumption of Cox proportional hazards models was checked with the use of log-minus-log plots, and was not violated. Significance level was set at Po0.05.
It was investigated whether cognitive impairment, CVD and functional impairment could be identified as mediators in the associations. Following Baron and Kenny (Holmbeck, 1997) , a mediating effect was identified if (1) the independent variable was associated with the dependent variable, (2) the independent variable was associated with the mediator, (3) the mediator was associated with the dependent variable and (4) the effect of het independent variable on dependent variable decreased substantial or disappeared when the mediator was added.
Results
A comparison of the excluded and included persons revealed that excluded persons (n ¼ 392) were older (Po0.000), had a lower level of education (P ¼ 0.006), were less physically active (Po0.000), were more likely to live in the region of the city Oss (P ¼ 0.047), used less alcohol (P ¼ 0.001), were more likely to be cognitively impaired (Po0.000), had suffered more CVD at baseline (Po0.000), and were more likely to be functionally impaired (Po0.000) compared with included respondents. Table 1 shows the baseline characteristics of the included men and women in the first and fourth quartile of homocysteine. Elevated homocysteine (X15 mmol/l) was observed in 35.8% of the study sample. Cut-off values of homocysteine quartiles in men were 11.96, 14.30 and 17.57 mmol/l, and in women 10.36, 12.68 and 15.64 mmol/l. Vitamin B12 deficiency (o150 pmol/l) was present in 4.2% of the study sample. The correlation coefficient with homocysteine was À0.36. Cut-off values of the vitamin B12 quartiles in men were 206, 254 and 308 pmol/l, and in women 220, 272 and 347 pmol/l.
Homocysteine and NH admission
During 6-year follow-up, 126 persons (11.3%), 39 men and 87 women, were admitted to a NH. Cox proportional hazards models did not show an association of homocysteine with risk of NH admission in men. In women, the fourth quartile of homocysteine was associated with a significantly higher risk of NH admission (hazard ratio (HR) ¼ 4.86, 95% confidence interval (CI) ¼ 2.43-9.72). In the multivariable models, the associations were somewhat less strong. However, in the fully adjusted model the association remained significant for the fourth versus the first quartile of homocysteine (HR ¼ 2.97, 95% CI ¼ 1.36-6.49) ( Table 2 and Figure 2 ).
Postulated risk factors as CVD and functional impairment were not associated with NH admission, after adjustment for basic confounders (Table 3) . Following the principles of Baron and Kenny (Holmbeck, 1997) , those variables were no longer candidate to mediate the association of homocysteine with NH admission. In contrast, cognitive impairment had a significant association with NH admission. Women who were cognitively impaired had a 2.83-fold risk to be admitted to a NH compared with women without cognitive impairment (Table 3) . Also, the other criteria to be a mediator were met for cognitive impairment (Table 4) . When both homocysteine and cognitive impairment were added to the model, the association between homocysteine and NH admission weakened. The HR decreased with 8.7%, but remained significant (Q4 HR ¼ 2.53, 95% CI ¼ 1.14-5.65).
Homocysteine and mortality
Between baseline and 1 June 2007, 513 persons (45.9%), including 301 men and 212 women, deceased. Men in the fourth quartile of homocysteine had a significant higher mortality risk compared with men in the lowest quartile (HR ¼ 1.83, 95% CI ¼ 1.33-2.54). However, after adjustment for confounding this associations were no longer significant. In women, the third as well as the fourth quartile were associated with a higher mortality risk (Q3 HR ¼ 2.08, 95% CI ¼ 1.36-3.17; Q4 HR ¼ 2.95, 95% CI ¼ 1.96-4.43). After adjustment for confounding these associations remained significant in both the third and in the fourth quartile (Q3 HR ¼ 1.70, 95% CI ¼ 1.08-2.65; Q4 HR ¼ 1.91, 95% CI ¼ 1.22-3.00) ( Table 5) .
CVD was not associated with mortality in women, after adjustment for basic confounders (Table 3) . Therefore, no mediating role in the association of homocysteine with mortality risk was identified. In contrast, being functionally or cognitively impaired increased the mortality risk 1.36-and 1.98-fold, respectively. The other conditions to be a mediator were only met for cognitive impairment. Adding cognitive impairment to the model weakened the association between homocysteine and mortality with a 
Discussion
The results of this study suggest that elevated plasma homocysteine concentrations are associated with a higher risk of NH admission and mortality in older women, independently of vitamin B12 status. No association was found in older men. Moreover, vitamin B12 was not associated with NH admission and mortality in both men and women. CVD: the presence of at least one of the diagnoses angina pectoris, myocardial infarction, congestive heart failure, peripheral arterial disease, cardiac arrhythmia or cerebro-vascular accident (including transient ischaemic attack); Functional impairment: having a score X2 on a 6-item functional impairment questionnaire.
This is the first study that focused on homocysteine in relation to NH admission. A limited number of studies investigated homocysteine in relation to disability and impairment. Marengoni et al. (2004) observed that high homocysteine concentrations were associated with functional impairment in acute hospitalised older persons. In addition, Kuo et al. (2007) observed that elevated homocysteine concentrations were related to multiple domains of disability in community dwelling older persons. Both studies are in line with the findings of the current study.
Previous studies on vitamin B12 showed conflicting results. A significant association between vitamin B12 deficiency and incident disability and the frailty syndrome (Matteini et al., 2008) was reported in two studies. However, two other studies failed to demonstrate an association between vitamin B12 and frailty (Michelon et al., 2006; Semba et al., 2006) . The latter findings were supported by the current results. Congruent with prior findings was that mortality was predicted by homocysteine, but not by vitamin B12 (Zeitlin et al., 1997; Dangour et al., 2008) , although the percentage of persons (4.2%) with vitamin B12 deficiency in this study was relatively low compared with other studies in similar populations (de Lau et al., 2009) . Moreover, in this study, the vitamin B12 analyses might be underpowered because vitamin B12 shows only a modest correlation with more sensitive measures for vitamin B12-bioavailablity, such as homocysteine and methylmalonic acid. The latter indicator was only available in a small subsample of the study sample and therefore not taken into account.
The current results suggest that homocysteine is associated with an increased mortality and NH admission risk in women only. Most previous studies on mortality risk with higher homocysteine concentrations did not explore modification by gender. To our knowledge, this issue was only addressed by Bostom et al. (1999) and Kark et al. (1999) . In contrast to our results, both studies did not report gender differences in the association. In this study, data from a large, population-based sample were used, with the opportunity to control for a wide range of confounding factors. The adjustment for socioeconomic status, here operationalised as education level, lifestyle factors, and vitamin B12 status was unique for this study. We studied the mediating effect of cognitive impairment, CVD and functional impairment in the association of homocysteine with the risk of NH admission and mortality. For a variable to be a mediator, a causal relation is assumed. Although the suggestion that elevated homocysteine is an independent risk factor for developing cognitive decline has been confirmed by several longitudinal studies (Seshadri et al., 2002; Haan et al., 2007) and one clinical trial (Durga et al., 2007) , other prospective studies (Luchsinger et al., 2004; Mooijaart et al., 2005) and clinical trials (Eussen et al., 2006; McMahon et al., 2006) failed to detect an association. The empirical support concerning homocysteine in relation with CVD also shows conflicting results, with epidemiologic studies clearly demonstrating homocysteine as an independent risk factor for atherosclerosis (Antoniades et al., 2009) , while intervention studies did not affect cardiovascular endpoints (Toole et al., 2004; Bonaa et al., 2006; Lonn et al., 2006) . Although the role of homocysteine in the aetiology of cognitive decline and CVD remains subject of ongoing debate, and the evidence for homocysteine as a risk factor for stroke is stronger than for CVD (Manolescu et al., 2010) , we choose to investigate the mediating role of those variables. Cognitive impairment partly mediated the association of homocysteine with mortality and only modestly with NH admission in women.
In contrast to cognitive impairment, neither CVD nor functional impairment was a mediator in the observed associations. A limitation of this study was that incident cognitive impairment, incident CVD and incident functional impairment, operationalised as time dependent variables, could not be included in the current analyses because of insufficient power. Hence, these events were not taken into account, while they might contribute to NH admission and/or mortality, especially during a long follow-up. Instead, the current analyses were performed with the variables measured at baseline. The mediating effects as found in this study could therefore be less precise.
Another limitation of this study is that the exact date of NH admission was not available. Admission was defined as the midpoint between two follow-up interviews, as was done in previous studies on NH admission . As such, information was lost and this may have led to a less precise estimation of the reported associations. In addition, the results may be an underestimation of the actual relationships as a result of selection bias, since those who were excluded were older, less physically active, more likely to be cognitively impaired, and had suffered more often CVD at baseline, compared with included respondents. Moreover, homocysteine was only measured at baseline. No information was available on vitamin B6, and measures of folic acid and methylmalonic acid were only performed in a small subsample. The influence of those variables could therefore not be taken into account. Furthermore, the measurement of cognitive impairment by the Mini Mental State Examination has some limitations, because the Mini Mental State Examination is influenced by age and education level, and is insensitive to mild cognitive impairment (Tombaugh and McIntyre, 1992) . Nonetheless, it is effective as screening instrument to differentiate persons with cognitive impairment from those without it. Since it is a widely used measure, its use makes the comparison across studies is possible.
Overall, the results of this study showed that homocysteine is a predictor of NH admission and mortality in older women, more powerful than other postulated factors as functional impairment and CVD. The association of homocysteine with mortality can be partly explained by cognitive impairment. As empirical support suggests that homocysteine and cognitive decline are causally related (Durga et al., 2007) , mortality might be reduced by decreasing homocysteine levels. Even if homocysteine is a marker of cognitive decline instead of a direct cause, homocysteine can be used as a risk marker for increased dependency.
